



OFFICIAL

RECEIVED  
CENTRAL FAX CENTER  
AUG 05 2004

**Facsimile Cover Sheet**

**To:** Commissioner for Patents  
U. S. Patent and Trademark Office

**Fax:** (703) 872-9306

**From:** Roberta P. Saxon, Ph. D.  
Reg. No. 43,087  
Patent Department

**Company:** Theravance, Inc.

**Telephone:** 650-808-3764

**Fax:** 650-808-6078

**Date:** August 5, 2004

**# of pages:** 4 (including this page)

**Re: Supplemental Information Disclosure Statement**

U. S. Serial Number 10/627,555

Attorney Docket No: P-154-US1

Examiner: Shailendra Kumar

Group Art Unit: 1621

Attached are the following documents:

1. Supplemental Information Disclosure Statement (2 pages)
2. Information Disclosure Statement by Applicant (Form PTO/SB/08a) - 1 page

**Certificate of Facsimile Transmission**

**Facsimile Number:** (703) 872-9306

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to Commissioner for Patents, United States Patent and Trademark Office at the facsimile number indicated above.

By: Barbara Bryant  
Barbara Bryant

Date: August 5, 2004

**Notice of Confidentiality**

The following transmittal contains confidential information intended exclusively for the above-named person. Use, copying, distribution or disclosure of information transmitted in error is strictly prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the enclosures to us.

PRIVILEGED AND CONFIDENTIAL

901 Gateway Blvd., South San Francisco, CA 94080; Tel. (650) 808-6000; Fax (650) 808-6078

OFFICIAL

RECEIVED 002  
CENTRAL FAX CENTER

AUG 05 2004

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile number (703) 872-9306 to Commissioner for Patents, United States Patent and Trademark Office, on the date shown below:

By: Barbara Bryant Date: August 5, 2004  
Barbara Bryant

Patent  
Attorney's Docket No. P-154-US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
MORAN et al.	)	Group Art Unit: 1621
	)	
Application No.: 10/627,555	)	Examiner: Shailendra Kumar
	)	
Filed: July 25, 2003	)	
	)	
For: CRYSTALLINE B <sub>2</sub> ADRENERGIC	)	
RECEPTOR AGONIST	)	
	)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is form PTO/SB/08a which lists documents for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Attorney Docket No. P-154-US1  
Application Serial No.: 10/627,555

Page 1 of 2

Additionally, Applicants hereby bring to the Examiner's attention the following commonly assigned application:

U. S. Serial No. 10/854,405, filed on May 26, 2004.

Copies of the U.S. patent and patent application publication cited on the accompanying PTO Form PTO/SB/08a have been omitted in accordance with the notice published August 5, 2003 in the Official Gazette 55, stating that the requirement under 37 CFR 1.98 (a)(2) for submitting such copies has been waived for U.S. national patent applications filed after June 30, 2003.

Consideration of the listed documents is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO/SB/08a to Applicants.

This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits for this application and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Should there be any questions concerning the cited documents, the Examiner is encouraged to telephone the undersigned agent for Applicants at (650) 808-3764 (direct).

Respectfully submitted,

THERAVANCE, INC.

Date: August 5, 2004

By:



Roberta P. Saxon, Ph.D.  
Registration No. 43,087

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078

Attorney Docket No. P-154-US1  
Application Serial No.: 10/627,555

Page 2 of 2

